<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653964</url>
  </required_header>
  <id_info>
    <org_study_id>12-004437</org_study_id>
    <nct_id>NCT01653964</nct_id>
  </id_info>
  <brief_title>Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing</brief_title>
  <acronym>Split-Dose</acronym>
  <official_title>Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friends for an Earlier Breast Cancer Test</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this work is to determine if half-dose Molecular Breast Imaging
      (MBI) performed with 4 mCi Tc-99m sestamibi with or without Wide Beam Reconstruction applied
      can achieve image quality and diagnostic accuracy non-inferior to that of standard MBI
      performed with 8 millicurie (mCi) Tc-99m sestamibi.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent implementation of dose reduction strategies for Molecular Breast Imaging now allow
      performance of MBI at an administered dose of 8 mCi Tc-99m sestamibi, which is reduced from
      the previously used doses of 20-30 mCi. In order to safely introduce MBI as a screening
      modality, we aim to perform MBI using 4 mCi Tc-99m sestamibi. An image processing algorithm
      called Wide Beam Reconstruction (WBR) has been tailored for MBI technology with the goal of
      allowing either the current administered dose or current acquisition time to be reduced by
      half.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the Diagnostic Accuracy of 8 mCi Molecular Breast Imaging (MBI) With 4 mCi MBI.</measure>
    <time_frame>At time of study (within 2 days after exam) and when enrollment has been reached (approximately 24 months)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Molecular breast imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Molecular breast imaging</intervention_name>
    <description>Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)</description>
    <arm_group_label>Molecular breast imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subgroup 1, Patients with breast lesions:

        -At least one breast lesion detected by mammogram, ultrasound or breast MRI that measures &lt;
        20 mm in greatest dimension, presents as a mass, is considered suspicious or highly
        suggestive of malignancy according to the Breast Imaging Reporting and Data System Atlas
        criteria (BIRADS 4 or 5), and is scheduled for core-needle biopsy or surgical biopsy.

        OR

        -At least one breast lesion that measures between &gt; 10 mm but &lt; 20 mm in greatest
        dimension, presents as a mass, is biopsy-proven as malignant, and is scheduled for surgical
        resection.

        AND

          -  Age &gt; 40 years

          -  Negative pregnancy test, postmenopausal, or surgically sterilized

        Subgroup 2, Patients without known breast lesions:

          -  Negative screening mammogram performed at Mayo Clinic Rochester within 15 months prior
             to performance of study MBI

          -  No signs or symptoms of breast disease

          -  Age &gt; 40 years

          -  Negative pregnancy test, postmenopausal, or surgically sterilized

        Exclusion Criteria:

          -  Vacuum-assisted or excisional biopsy has been performed prior to the study MBI.
             Reason: these types of biopsies are more likely to remove all of the tumor

          -  MBI is performed after biopsy and neo-adjuvant chemotherapy is planned prior to
             surgery. Reason: true tumor size will not be able to be ascertained from the final
             pathology findings

          -  Breast implants. Reason: cases with breast implants will be easily identifiable on
             blinded interpretation to take place at the study end

          -  Suspected that breasts will not fit in the MBI field of view. Reason: cases that
             require tiled views or additional views will be easily identifiable on blinded
             interpretation to take place at the study end

          -  Only one breast remaining. Reason: unilateral cases will be easily identifiable on
             blinded interpretation to take place at the study end; injection timing is designed
             for bilateral views

          -  Pregnancy test (if necessary) is not negative, or the patient is unable to complete
             the pregnancy test

          -  Physically unable to sit upright and still remain still during two consecutive MBI
             studies over the course of a 2-hour period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carrie B Hruska, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://newsblog.mayoclinic.org/2008/09/03/breast-cancer-molecular-breast-imaging-mammography/</url>
    <description>Mayo Clinic News</description>
  </link>
  <link>
    <url>http://www.youtube.com/watch?v=DOQBLe8MdH0</url>
    <description>Mayo Clinic You Tube Channel</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <results_first_submitted>April 28, 2017</results_first_submitted>
  <results_first_submitted_qc>September 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Carrie Hruska</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>suspicious</keyword>
  <keyword>lesion</keyword>
  <keyword>breast</keyword>
  <keyword>cancer</keyword>
  <keyword>screening</keyword>
  <keyword>mammogram</keyword>
  <keyword>negative</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>83 subjects were enrolled (consented) but 1 subject was found not to meet eligibility criteria, so did not participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Molecular Breast Imaging</title>
          <description>Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 millicurie (mCi) Tc-99m sestamibi.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Molecular Breast Imaging</title>
          <description>Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compare the Diagnostic Accuracy of 8 mCi Molecular Breast Imaging (MBI) With 4 mCi MBI.</title>
        <time_frame>At time of study (within 2 days after exam) and when enrollment has been reached (approximately 24 months)</time_frame>
        <population>Of 82 patients recruited to the study (prior to breast biopsy), 34 had a histologically-proven diagnosis of breast cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Molecular Breast Imaging</title>
            <description>Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.</description>
          </group>
        </group_list>
        <measure>
          <title>Compare the Diagnostic Accuracy of 8 mCi Molecular Breast Imaging (MBI) With 4 mCi MBI.</title>
          <population>Of 82 patients recruited to the study (prior to breast biopsy), 34 had a histologically-proven diagnosis of breast cancer.</population>
          <units>cancers detected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 mCi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 mCi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day of study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Molecular Breast Imaging</title>
          <description>Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
Molecular breast imaging: Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carrie Hruska</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>5072663991</phone>
      <email>hruska.carrie@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

